Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) gapped down before the market opened on Wednesday . The stock had previously closed at $23.38, but opened at $21.85. Dianthus Therapeutics shares last traded at $23.05, with a volume of 21,600 shares.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DNTH. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Trading Down 5.5 %

The firm has a market cap of $653.95 million, a PE ratio of -8.81 and a beta of 1.82. The company has a 50 day moving average price of $22.65 and a 200 day moving average price of $24.97.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently modified their holdings of DNTH. R Squared Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $26,000. Quest Partners LLC raised its holdings in shares of Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at $35,000. Finally, BNP Paribas Financial Markets purchased a new stake in Dianthus Therapeutics during the 4th quarter worth about $59,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.